Female sex (11, 12)Younger age (11)Caucasian ethnicity (12)Combined CTLA-4 + PD-1 treatment (11, 12)Longer duration of anti-PD-1 treatment (16)Higher body mass index (17)Renal cell carcinoma* (12)Baseline TSH (8, 16–18)Baseline TPOAb positivity; treatment related increase in TPOAb titer (14, 16, 19)Baseline TgAb positivity; treatment related increase in TPOAb titer (14, 16, 18, 19). This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.